Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Volume 1863, Issue 9, Pages 2171-2181Publisher
ELSEVIER
DOI: 10.1016/j.bbadis.2017.06.004
Keywords
TUDCA; Parkinson's disease; Oxidative stress; Mitochondria; Mitophagy; Parkin
Funding
- Fundacdo para a Ciencia e a Tecnologia (FCT), Portugal [PTDC/NEU-NMC/0248/2012, UID/DTP/04138/2013, SFRH/BPD72891/2010, SFRH/BPD/95855/2013, SFRH/BPD/98023/2013]
- Fundação para a Ciência e a Tecnologia [PTDC/NEU-NMC/0248/2012, SFRH/BPD/98023/2013] Funding Source: FCT
Ask authors/readers for more resources
Impaired mitochondrial function and generation of reactive oxygen species are deeply implicated in Parkinson's disease progression. Indeed, mutations in genes that affect mitochondrial function account for most of the familial cases of the disease, and post mortem studies in sporadic PD patients brains revealed increased signs of oxidative stress. Moreover, exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a mitochondrial complex I inhibitor, leads to clinical symptoms similar to sporadic PD. The bile acid tauroursodeoxycholic acid (TUDCA) is an anti-apoptotic molecule shown to protect against MPTP-induced neurodegeneration in mice, but the mechanisms involved are still incompletely identified. Herein we used MPTP-treated mice, as well as primary cultures of mice cortical neurons and SH-SY5Y cells treated with MPP to investigate the modulation of mitochondrial dysfunction by TUDCA in PD models. We show that TUDCA exerts its neuroprotective role in a parkin-dependent manner. Overall, our results point to the pharmacological up-regulation of mitochondrial turnover by TUDCA as a novel neuroprotective mechanism of this molecule, and contribute to the validation of TUDCA clinical application in PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available